Cargando…

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome

Twenty-six cases of B cell lymphoproliferative disorder (BLPD) were identified among 2395 patients following hematopoietic stem cell transplants (HSCT) for which an overall incidence of BLPD was 1.2%. The true incidence was probably higher, since 9/26 of the diagnoses were made at autopsy. No BLPD w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gross, TG, Steinbuch, M, DeFor, T, Shapiro, RS, McGlave, P, Ramsay, NKC, Wagner, JE, Filipovich, AH
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 1999
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091602/ https://www.ncbi.nlm.nih.gov/pubmed/10084256 http://dx.doi.org/10.1038/sj.bmt.1701554

Ejemplares similares

Hematopoietic Stem Cell Transplantation after Posttransplant Lymphoproliferative Disorder
por: Kim, Min Joo, et al.
Publicado: (2010)

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation
por: Long-Boyle, Janel R, et al.
Publicado: (2010)

Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
por: Fonseca-Hial, Ana Marcela Rojas, et al.
Publicado: (2016)

Clinical Characteristics and Outcomes of Posttransplant Lymphoproliferative Disorders Following Allogeneic Hematopoietic Stem Cell Transplantation in Korea
por: Park, Sun Hee, et al.
Publicado: (2006)

Factors Predicting Single-Unit Predominance after Double Umbilical Cord Blood Transplantation
por: Ramirez, Pablo, et al.
Publicado: (2011)

Endobronchial Epstein-Barr Virus Associated Post-transplant Lymphoproliferative Disorder in Hematopoietic Stem Cell Transplantation
por: Feuillet, S., et al.
Publicado: (2009)

Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
por: Clerico, Michele, et al.
Publicado: (2022)

Management of Epstein–Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
por: Liu, Li, et al.
Publicado: (2020)

MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes
por: Pourhassan, H, et al.
Publicado: (2016)

Hematopoietic cell transplantation for asymptomatic X-linked lymphoproliferative syndrome type 1
por: Tamura, Akihiro, et al.
Publicado: (2018)

Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation
por: Kopińska, Anna, et al.
Publicado: (2012)

Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders
por: Sawada, Akihisa, et al.
Publicado: (2018)

Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience
por: Sakamoto, Hikaru, et al.
Publicado: (2019)

National Trends and Outcomes Associated With Presence and Type of Usual Clinician Among Older Adults With Multimorbidity
por: Ganguli, Ishani, et al.
Publicado: (2021)

Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment
por: Overkamp, Mathis, et al.
Publicado: (2020)

Application of contrast-enhanced ultrasound in the diagnosis of post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation: A case report
por: Chen, Weinan, et al.
Publicado: (2021)

Diagnosis and treatment of neoplastic post-transplant lymphoproliferative disorder following hematopoietic stem cell transplant in β-thalassemia: A pediatric case report
por: Zhang, Xiaohong, et al.
Publicado: (2017)

Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience
por: Zhu, Cheng-ying, et al.
Publicado: (2019)

Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes
por: Fujimoto, Ayumi, et al.
Publicado: (2020)

Transient regulatory T-cell (Treg) depletion with IL-2 diphtheria toxin fusion protein enhances clearance of acute myeloid leukemia by haploidentical natural killer (NK) cells
por: Bachanova, Veronika, et al.
Publicado: (2013)

Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus–Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplantation
por: Ainley, Louise, et al.
Publicado: (2020)

Hodgkin's disease as unusual presentation of post-transplant lymphoproliferative disorder after autologous hematopoietic cell transplantation for malignant glioma
por: Zambelli, Alberto, et al.
Publicado: (2005)

Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
por: Yang, Ting-Ting, et al.
Publicado: (2021)

Hematopoietic stem cell transplantation
por: Hatzimichael, Eleftheria, et al.
Publicado: (2010)

Hematopoietic Stem Cell Transplantation
por: Maedler-Kron, Chelsea, et al.
Publicado: (2016)

SIRT1-SIRT7 Expression in Patients with Lymphoproliferative Disorders Undergoing Hematopoietic Stem Cell Mobilization
por: Nowicki, Mateusz, et al.
Publicado: (2022)

Epstein–Barr virus-associated posttransplant lymphoproliferative disorder involving the central nervous system following autologous hematopoietic stem cell transplantation for neuroblastoma
por: Sano, Hitoshi, et al.
Publicado: (2014)

Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell Transplant
por: Malhotra, Bharat, et al.
Publicado: (2015)

Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis
por: Enok Bonong, Pascal Roland, et al.
Publicado: (2021)

Hematopoietic Neoplasias in Horses: Myeloproliferative and Lymphoproliferative Disorders
por: MUÑOZ, Ana, et al.
Publicado: (2010)

Long-term health outcomes of allogeneic hematopoietic stem cell transplantation
por: Kelkar, Amar H., et al.
Publicado: (2023)

Trends in 340B Drug Pricing Program Contract Growth Among Retail Pharmacies From 2009 to 2022
por: Nikpay, Sayeh, et al.
Publicado: (2023)

Gastrointestinal Complications Following Hematopoietic Stem Cell Transplantation in Children
por: Lee, Ji-Hye, et al.
Publicado: (2008)

Haploidentical hematopoietic cell transplant recipient presents with late‐onset Epstein Barr virus‐associated posttransplant lymphoproliferative disorder
por: Braun, Adam, et al.
Publicado: (2023)

Successful treatment of early onset Epstein-Barr virus-negative T-cell lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation with histone deacetylase inhibitor chidamide
por: Fu, Hua-Rui, et al.
Publicado: (2021)

Practical Hematopoietic Stem Cell Transplantation
por: Tworkoski, Kathryn
Publicado: (2009)

CMV in Hematopoietic Stem Cell Transplantation
por: de la Cámara, Rafael
Publicado: (2016)

New Allogeneic Hematopoietic Stem Cell Transplantation Method: Hematopoietic Stem Cell Transplantation Plus Thymus Transplantation for Intractable Diseases
por: Hosaka, Naoki
Publicado: (2013)

Natural Killer Cells in Post-Transplant Lymphoproliferative Disorders
por: Nakid-Cordero, Cecilia, et al.
Publicado: (2021)

Late Epstein-Barr virus-related post-transplant lymphoproliferative disorder with intestinal involvement in patient with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
por: HJELLBAKK, HEDDA KLOSTER, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_krp5i4rom5l9qf0skh868vr4vk